Cited 2 time in
Incidence and Clinical Outcomes of Febrile Neutropenia in Adult Cancer Patients with Chemotherapy Using Korean Nationwide Health Insurance Database
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kim, Dalyong | - |
| dc.contributor.author | Lee, Soohyeon | - |
| dc.contributor.author | Youk, Taemi | - |
| dc.contributor.author | Hong, Soojung | - |
| dc.date.accessioned | 2023-04-27T17:40:38Z | - |
| dc.date.available | 2023-04-27T17:40:38Z | - |
| dc.date.issued | 2021-06 | - |
| dc.identifier.issn | 0513-5796 | - |
| dc.identifier.issn | 1976-2437 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/4947 | - |
| dc.description.abstract | Purpose: The aim of this study was to evaluate the episodes of febrile neutropenia (FN) in patients with gastric cancer (GC), colorectal cancer (CRC), lung cancer (LC), and breast cancer (BC); and to identify the incidence and trends of admission rates, as well as factors affecting mortality. Materials and Methods: Using nationwide claims data, all new admissions to hospitals for FN were selected. We evaluated the incidence of FN and mortality-related clinical factors in adult cancer patients who received cytotoxic chemotherapy from January 2004 to December 2013. Results: While the incidence of FN increased, the length of hospitalization decreased in Korea. The incidence of FN was 19.8% in LC patients, 15.5% in GC patients, 13.3% in BC patients, and 9.5% in CRC patients. The overall in-hospital mortality of FN was 12.9% and showed a decreasing trend. Admission rates to intensive care units and in-hospital mortality were the highest for lung cancer (15.2% and 19.3%, respectively). Age and sepsis syndrome were risk factors for in-hospital mortality for all cancer types. Conclusion: Careful observation and active prophylaxis should be considered for patients at high risk of FN. | - |
| dc.format.extent | 8 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | YONSEI UNIV COLL MEDICINE | - |
| dc.title | Incidence and Clinical Outcomes of Febrile Neutropenia in Adult Cancer Patients with Chemotherapy Using Korean Nationwide Health Insurance Database | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.3349/ymj.2021.62.6.479 | - |
| dc.identifier.scopusid | 2-s2.0-85106749536 | - |
| dc.identifier.wosid | 000654314000002 | - |
| dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, v.62, no.6, pp 479 - 486 | - |
| dc.citation.title | YONSEI MEDICAL JOURNAL | - |
| dc.citation.volume | 62 | - |
| dc.citation.number | 6 | - |
| dc.citation.startPage | 479 | - |
| dc.citation.endPage | 486 | - |
| dc.type.docType | Article | - |
| dc.identifier.kciid | ART002717439 | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | General & Internal Medicine | - |
| dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
| dc.subject.keywordPlus | ECONOMIC BURDEN | - |
| dc.subject.keywordPlus | COST | - |
| dc.subject.keywordPlus | MANAGEMENT | - |
| dc.subject.keywordPlus | MORTALITY | - |
| dc.subject.keywordPlus | FLUOROURACIL | - |
| dc.subject.keywordPlus | OXALIPLATIN | - |
| dc.subject.keywordPlus | LEUCOVORIN | - |
| dc.subject.keywordPlus | CARE | - |
| dc.subject.keywordAuthor | Chemotherapy | - |
| dc.subject.keywordAuthor | febrile neutropenia | - |
| dc.subject.keywordAuthor | national health insurance | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
